Norgine; AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals and Norgine B.V. Enter Into Exclusive Licensing Agreement to Commercialize Ciraparantag in Europe, Australia and New Zealand
Waltham, Mass. and Amsterdam (ots/PRNewswire) - Agreement provides AMAG with $30 million upfront payment and eligibility to receive up to $260 million in development and commercial milestones in addition to sales royalties Collaboration further advances the development of ciraparantag AMAG Pharmaceuticals, Inc. ...
mehr